{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T06:40:41Z","timestamp":1777876841953,"version":"3.51.4"},"reference-count":45,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2023YFC2506404"],"award-info":[{"award-number":["2023YFC2506404"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Beijing Research Ward Excellence Program","award":["BRWEP, BRWEP2024W032150200, BRWEP2024W032150202"],"award-info":[{"award-number":["BRWEP, BRWEP2024W032150200, BRWEP2024W032150202"]}]},{"DOI":"10.13039\/501100004826","name":"natural science foundation of beijing municipality","doi-asserted-by":"publisher","award":["7242021"],"award-info":[{"award-number":["7242021"]}],"id":[{"id":"10.13039\/501100004826","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009601","name":"Beijing Municipal Administration of Hospitals\u2019 Ascent Plan","doi-asserted-by":"crossref","award":["DFL20220901"],"award-info":[{"award-number":["DFL20220901"]}],"id":[{"id":"10.13039\/501100009601","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Ther Adv Med Oncol"],"published-print":{"date-parts":[[2026,4]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Programmed cell death protein (PD-1) inhibitors constitute the standard adjuvant therapy for cutaneous melanoma (CM), but well-established strategies for acral melanoma (AM) remain limited.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>To compare the efficacy of adjuvant anti-PD-1 immunotherapy versus high-dose interferon \u03b1-2b (HDI) in patients with stage IIB-IV AM and CM.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design:<\/jats:title>\n                    <jats:p>This multicenter, retrospective study enrolled 511 patients with resected stage IIB-IV AM and CM between January 2017 and December 2023.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>Patients were divided into four groups by subtype and treatment: patients with CM and treated with anti-PD-1 (CM-PD-1), patients with CM and treated with HDI (CM-HDI), patients with AM and treated with anti-PD-1 (AM-PD-1), and patients with AM and treated with HDI (AM-HDI). Recurrence-free survival (RFS), overall survival (OS), and patient safety were evaluated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      This study comprised 362\u2009AM and 149 CM cases. AM cases presented with thicker primary lesions, higher ulceration rates, and fewer\n                      <jats:italic toggle=\"yes\">BRAF<\/jats:italic>\n                      mutations. Median follow-up was 49\u2009months. Among patients with stage IIB\/C, median RFS was not reached in any groups. Among stage III\/IV patients, median RFS was 14.6 (CM-PD-1), 13.7 (CM-HDI), 13.3 (AM-PD-1), and 11.7\u2009months (AM-HDI), and median OS was 61.6, 40.7, 42.4, and 53.4\u2009months, respectively, without significant intergroup differences. Anti-PD-1 significantly improved RFS in patients with stage III\/IV AM with\n                      <jats:italic toggle=\"yes\">KIT<\/jats:italic>\n                      mutations (9.1 vs 5.0\u2009months,\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      \u2009=\u20090.048) and \u2a7e4 lymph node metastases (10.5 vs 6.6\u2009months,\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      \u2009=\u20090.036). Anti-PD-1 had significantly fewer adverse effects than HDI (60.4% vs 88.6%,\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      \u2009&lt;\u20090.001), including fewer grades 3\u20134 events (4.6% vs 30.7%,\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      \u2009&lt;\u20090.001).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>\n                      Adjuvant anti-PD-1 therapy provides RFS comparable to that of HDI in AM and CM, with a superior safety profile. Patients with AM harboring\n                      <jats:italic toggle=\"yes\">KIT<\/jats:italic>\n                      mutations derive greater benefits from adjuvant anti-PD-1 therapy.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/17588359261436189","type":"journal-article","created":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T11:02:16Z","timestamp":1776855736000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Anti-PD-1 matches interferon as adjuvant therapy for acral melanoma: a retrospective study"],"prefix":"10.1177","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2491-9308","authenticated-orcid":false,"given":"Yu","family":"Du","sequence":"first","affiliation":[{"name":"Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education, Beijing), Department of Melanoma and Sarcoma, Peking University Cancer Hospital and Institute, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Fujian Cancer Hospital and Fujian Medical University Cancer Hospital, Fuzhou, Fujian Province, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiaxiang","family":"Wang","sequence":"additional","affiliation":[{"name":"Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education, Beijing), Department of Melanoma and Sarcoma, Peking University Cancer Hospital and Institute, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Fujian Cancer Hospital and Fujian Medical University Cancer Hospital, Fuzhou, Fujian Province, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoting","family":"Wei","sequence":"additional","affiliation":[{"name":"Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education, Beijing), Department of Melanoma and Sarcoma, Peking University Cancer Hospital and Institute, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junjie","family":"Gu","sequence":"additional","affiliation":[{"name":"Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education, Beijing), Department of Melanoma and Sarcoma, Peking University Cancer Hospital and Institute, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Guo","sequence":"additional","affiliation":[{"name":"Department of Melanoma and Sarcoma, Peking University Cancer Hospital and Institute, 52 Fucheng Road, Haidian District, Beijing 100142, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lu","family":"Si","sequence":"additional","affiliation":[{"name":"Department of Melanoma and Sarcoma, Peking University Cancer Hospital and Institute, 52 Fucheng Road, Haidian District, Beijing 100142, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lili","family":"Mao","sequence":"additional","affiliation":[{"name":"Department of Melanoma and Sarcoma, Peking University Cancer Hospital and Institute, 52 Fucheng Road, Haidian District, Beijing 100142, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2026,4,22]]},"reference":[{"key":"e_1_3_4_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdermsci.2019.04.003"},{"key":"e_1_3_4_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0025-6196(11)61033-1"},{"key":"e_1_3_4_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.semcancer.2019.10.017"},{"key":"e_1_3_4_5_2","doi-asserted-by":"publisher","DOI":"10.1111\/ced.13243"},{"key":"e_1_3_4_6_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-21-3344"},{"key":"e_1_3_4_7_2","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.524700"},{"key":"e_1_3_4_8_2","doi-asserted-by":"publisher","DOI":"10.1038\/nature22071"},{"key":"e_1_3_4_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2017.03.018"},{"key":"e_1_3_4_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2017.03.025"},{"key":"e_1_3_4_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2018.11.008"},{"key":"e_1_3_4_12_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1709030"},{"key":"e_1_3_4_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30417-7"},{"key":"e_1_3_4_14_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1802357"},{"key":"e_1_3_4_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00065-6"},{"key":"e_1_3_4_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2019.05.020"},{"key":"e_1_3_4_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)00562-1"},{"key":"e_1_3_4_18_2","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-21-1141"},{"key":"e_1_3_4_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2011.09.028"},{"key":"e_1_3_4_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.05.031"},{"key":"e_1_3_4_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2019.02.007"},{"key":"e_1_3_4_22_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-3922"},{"key":"e_1_3_4_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)61602-X"},{"key":"e_1_3_4_24_2","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2014.32.15_suppl.9067"},{"key":"e_1_3_4_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2011.03.019"},{"key":"e_1_3_4_26_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-020-00913-6"},{"key":"e_1_3_4_27_2","doi-asserted-by":"publisher","DOI":"10.3390\/ph16010041"},{"key":"e_1_3_4_28_2","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.6234"},{"key":"e_1_3_4_29_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02583-2"},{"key":"e_1_3_4_30_2","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.21241"},{"key":"e_1_3_4_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2024.113563"},{"key":"e_1_3_4_32_2","doi-asserted-by":"publisher","DOI":"10.1097\/CJI.0000000000000508"},{"key":"e_1_3_4_33_2","doi-asserted-by":"publisher","DOI":"10.1111\/dth.15067"},{"key":"e_1_3_4_34_2","doi-asserted-by":"publisher","DOI":"10.1111\/dth.15817"},{"key":"e_1_3_4_35_2","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.35060"},{"key":"e_1_3_4_36_2","doi-asserted-by":"publisher","DOI":"10.2340\/actadv.v102.678"},{"key":"e_1_3_4_37_2","doi-asserted-by":"publisher","DOI":"10.1093\/bjd\/ljad183"},{"key":"e_1_3_4_38_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)70076-8"},{"key":"e_1_3_4_39_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.27.1627"},{"key":"e_1_3_4_40_2","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21409"},{"key":"e_1_3_4_41_2","doi-asserted-by":"publisher","DOI":"10.1002\/jso.25343"},{"key":"e_1_3_4_42_2","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-11-85"},{"key":"e_1_3_4_43_2","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.21026"},{"key":"e_1_3_4_44_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2022.08.052"},{"key":"e_1_3_4_45_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-023-05127-w"},{"key":"e_1_3_4_46_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjsurg.2013.09.003"}],"container-title":["Therapeutic Advances in Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/17588359261436189","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/17588359261436189","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/17588359261436189","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T22:34:24Z","timestamp":1777588464000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/17588359261436189"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":45,"alternative-id":["10.1177\/17588359261436189"],"URL":"https:\/\/doi.org\/10.1177\/17588359261436189","relation":{},"ISSN":["1758-8359","1758-8359"],"issn-type":[{"value":"1758-8359","type":"print"},{"value":"1758-8359","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4]]},"article-number":"17588359261436189"}}